Bernie Sanders Takes Aim at Ozempic's Pricing in the U.S. Senate
Tuesday, 24 September 2024, 10:03
Bernie Sanders Addresses Ozempic Pricing
In a recent U.S. Senate hearing, Bernie Sanders confronted the executives of Novo Nordisk regarding the escalating prices of their weight-loss drugs, specifically Ozempic and Wegovy. He emphasized that such high costs are detrimental to public health and disproportionately affect Americans seeking effective weight-management solutions. Sanders argues that the weight-loss and diet control industry must prioritize patient well-being over profits.
The Impact on Patients
- Patients struggle to afford necessary medications.
- High prices limit access to effective weight-loss solutions.
- Increased public scrutiny on pharmaceutical pricing practices.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.